Clinical trial · Interventional
Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery
NCT04449289CI-TRIAL-00045690unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery. As short term endpoints: postoperative complications and resumption of bowel function. Long term endpoints include: 1 and 3 year recurrence and mortality.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epidural ropivacaine | Drug | — | UNRESOLVED |
| Intravenous lidocaine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Intravenous lidocaine
- description
- Patients will be subjected to anesthesia with sevoflurane+fentanyl+intravenous lidocaine infusion for the first 48 hours postoperative
- interventionNames
- Drug: Intravenous lidocaine
- type
- ACTIVE_COMPARATOR
- label
- Epidural ropivacaine
- description
- Patients will be subjected to anesthesia with sevoflurane+fentanyl+epidural ropivacaine infusion for the first 48 hours postoperatively
- interventionNames
- Drug: Epidural ropivacaine
Primary outcomes (1)
- measure
- 1- and 3-years recurrence rate after surgery
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of pancreatic cancer * American Society of Anesthesiologists (ASA) risk I - III Exclusion Criteria: * chronic pain * chronic medication that may interfere with pain: antiepileptics, NSAID, corticoids * contraindications for any of the study medications * significant psychiatric disorders (major depression, bipolar disorders, schizophrenia, etc.) * Convulsive disorders requiring medication during the last 2 years * liver cirrhosis/chronic kidney disease stage IV or V/chronic heart failure class III or IV/ decompensated diabetes * Corticoid dependent asthma * Autoimmune disorders * Anti-arrhythmic medication (verapamil, propafenone, amiodarone) that may interfere with lidocaine's anti-arrhythmic effects * Refusal for study participation
References
Publications (0)
Data not yet available
No reference posted for this study.